---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011775"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:27:59.757678+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Processa receives second 180-day grace period to regain Nasdaq bid price compliance

## Summary
- Grace period runs until February 2, 2026 to meet $1.00 minimum bid price.
- Compliance requires closing bid price ≥ $1.00 for 10 consecutive business days.
- Company will consider a reverse stock split if needed to cure deficiency.
- Common stock continues trading on Nasdaq Capital Market during the period.

## SEC filing metadata
- accession: 0001493152-25-011775
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315225011775/0001493152-25-011775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315225011775/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011775
- JSON: https://secwatch.observer/filing/0001493152-25-011775.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011775.txt

## Key facts
- Listing & Compliance Notices
  Processa Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: August 7, 2025, the Company received a letter from the Staff notifying that the Company is eligible for a second 180-day period, or until February 2, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the minimum bid price requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315225011775/0001493152-25-011775-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.